Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Fukami, Kei ^a,b   Yamagishi, Sho Ichi ^a   Coughlan, Melinda T ^b,c   Harcourt, Brooke E ^b,d   Kantharidis, Phillip ^b   Thallas Bonke, Vicki ^b   Okuda, Seiya ^a   Cooper, Mark E ^b   Forbes, Josephine M ^b,d  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Advanced glycation end products; Diabetic nephropathy; MMP 2; NF B; RAGE; Renin angiotensin system

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN II; GELATINASE A; RAMIPRIL; RAMIPRILAT; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS;

EID: 84908089004     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-86     Document Type: Article

References (51)

1. Evolving natural history of coronary artery disease in diabetes mellitus. Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LM, Christlieb AR, Am J Med 1991 90 2A 56S 61S
2. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P, Am J Kidney Dis 2000 35 1 157 165
3. Renal structure and function in insulin-dependent diabetes mellitus and type I membranoproliferative glomerulonephritis in humans. Mauer SM, Lane P, Hattori M, Fioretto P, Steffes MW, J Am Soc Nephrol 1992 2 10 Suppl 181 S184
4. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Sharma K, Ziyadeh FN, Diabetes 1995 44 10 1139 1146
5. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI, Diabetes 1994 43 8 1046 1051
6. The renal tubulointerstitium in diabetes mellitus. Ziyadeh FN, Goldfarb S, Kidney Int 1991 39 3 464 475
7. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. Brownlee M, Cerami A, Vlassara H, N Engl J Med 1988 318 20 1315 1321
8. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. Grandhee SK, Monnier VM, J Biol Chem 1991 266 18 11649 11653
9. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW, J Biol Chem 1991 266 18 11654 11660
10. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, Group DSCAS, Diabetes 2005 54 11 3103 3111
11. Advanced glycation end products and diabetic nephropathy. Thomas MC, Forbes JM, Cooper ME, Am J Ther 2005 12 6 562 572
12. Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Nożyński J, Zakliczyński M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, Rdzanowska K, Lange D, Przybylski R, Zembala M, Ann Transplant 2012 17 2 53 61
13. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M, Diabetes 2005 54 11 3274 3281
14. Role of AGEs in diabetic nephropathy. Fukami K, Yamagishi S, Ueda S, Okuda S, Curr Pharm Des 2008 14 10 946 952
15. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM, J Am Soc Nephrol 2009 20 4 742 752
16. Extracellular matrix metabolism in diabetic nephropathy. Mason RM, Wahab NA, J Am Soc Nephrol 2003 14 5 1358 1373
17. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. Karagiannis ED, Popel AS, J Biol Chem 2004 279 37 39105 39114
18. Matrix metalloproteinases in renal development and disease. Lenz O, Elliot SJ, Stetler-Stevenson WG, J Am Soc Nephrol 2000 11 3 574 581
19. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Nagano M, Fukami K, Yamagishi S, Ueda S, Kaida Y, Matsumoto T, Yoshimura J, Hazama T, Takamiya Y, Kusumoto T, Gohara S, Tanaka H, Adachi H, Okuda S, Am J Nephrol 2009 29 2 109 115
20. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL, Diabetes Care 2007 30 9 2321 2326
21. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Cheng S, Lovett DH, Am J Pathol 2003 162 6 1937 1949
22. Myofibroblasts and the progression of diabetic nephropathy. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB, el Nahas AM, Nephrol Dial Transplant 1997 12 1 43 50
23. Why is proteinuria an ominous biomarker of progressive kidney disease? Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM, Kidney Int Suppl 2004 92 76 S89
24. Novel therapeutic targets for diabetic nephropathy. Fukami K, Yamagishi S, Ueda S, Okuda S, Endocr Metab Immune Disord Drug Targets 2007 7 2 83 92
25. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, N Engl J Med 1993 329 20 1456 1462
26. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, N Engl J Med 2011 364 10 907 917
27. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, N Engl J Med 2001 345 12 861 869
28. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S, Kidney Int 2004 66 6 2137 2147
29. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Pharmacol Res 2010 61 1 34 39
30. Telmisartan inhibits AGE-induced podocyte damage and detachment. Fukami K, Yamagishi S, Kaifu K, Matsui T, Kaida Y, Ueda S, Takeuchi M, Asanuma K, Okuda S, Microvasc Res 2013 88 79 83
31. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME, Faseb J 2003 17 12 1762 1764
32. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM, Diabetes 2002 51 11 3274 3282
33. Validation in awake rats of a tail-cuff method for measuring systolic pressure. Bunag RD, J Appl Physiol 1973 34 2 279 282
34. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME, J Clin Invest 2001 108 12 1853 1863
35. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME, J Am Soc Nephrol 2005 16 8 2363 2372
36. Primary kidney cells. Taub M, Methods Mol Biol 1997 75 153 161
37. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM, Endocrinology 2007 148 2 886 895
38. Renoprotective effects of a novel inhibitor of advanced glycation. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME, Diabetologia 2001 44 1 108 114
39. Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. Lewis MP, Fine LG, Norman JT, Kidney Int 1996 49 1 48 58
40. Isolation of a pure suspension of rat proximal tubules. Vinay P, Gougoux A, Lemieux G, Am J Physiol 1981 241 4 403 F411
41. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME, J Biol Chem 1997 272 34 21096 21103
42. Isolation and characterization of a primary proximal tubular epithelial cell model from human kidney by CD10/CD13 double labeling. Van der Hauwaert C, Savary G, Gnemmi V, Glowacki F, Pottier N, Bouillez A, Maboudou P, Zini L, Leroy X, Cauffiez C, Perrais M, Aubert S, PLoS One 2013 8 6 66750
43. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H, FEBS Lett 2005 579 20 4265 4270
44. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Saisho Y, Komiya N, Hirose H, Diabetes Res Clin Pract 2006 74 2 201 203
45. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Yamagishi S, Imaizumi T, Curr Pharm Des 2005 11 18 2279 2299
46. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA, Diabetes 2008 57 9 2461 2469
47. The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Du H, Li P, Wang J, Qing X, Li W, Cell Mol Neurobiol 2012 32 1 141 147
48. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM, J Clin Invest 2000 105 8 1117 1124
49. Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension. Cau SB, Guimaraes DA, Rizzi E, Ceron CS, Souza LL, Tirapelli CR, Gerlach RF, Tanus-Santos JE, Br J Pharmacol 2011 164 2 372 381
50. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G, Diabetologia 1997 40 12 1449 1454
51. Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats. Iwazu Y, Muto S, Hirahara I, Fujisawa G, Takeda S, Kusano E, J Hypertens 2011 29 12 2440 2453